Kyung Dong Pharmaceutical Co. Ltd (011040) - Net Assets
Based on the latest financial reports, Kyung Dong Pharmaceutical Co. Ltd (011040) has net assets worth ₩231.58 Billion KRW (≈ $156.94 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩307.84 Billion ≈ $208.62 Million USD) and total liabilities (₩76.26 Billion ≈ $51.68 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Kyung Dong Pharmaceutical Co. Ltd (011040) strategic asset index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩231.58 Billion |
| % of Total Assets | 75.23% |
| Annual Growth Rate | 3.03% |
| 5-Year Change | -11.91% |
| 10-Year Change | 9.03% |
| Growth Volatility | 6.94 |
Kyung Dong Pharmaceutical Co. Ltd - Net Assets Trend (2011–2025)
This chart illustrates how Kyung Dong Pharmaceutical Co. Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Kyung Dong Pharmaceutical Co. Ltd market cap and net worth.
Annual Net Assets for Kyung Dong Pharmaceutical Co. Ltd (2011–2025)
The table below shows the annual net assets of Kyung Dong Pharmaceutical Co. Ltd from 2011 to 2025. Also explore 011040 shareholders equity momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩228.87 Billion ≈ $155.10 Million |
+4.00% |
| 2024-12-31 | ₩220.06 Billion ≈ $149.13 Million |
-3.68% |
| 2023-12-31 | ₩228.48 Billion ≈ $154.84 Million |
-11.17% |
| 2022-12-31 | ₩257.20 Billion ≈ $174.30 Million |
-1.01% |
| 2021-12-31 | ₩259.82 Billion ≈ $176.08 Million |
-0.90% |
| 2020-12-31 | ₩262.19 Billion ≈ $177.68 Million |
+15.65% |
| 2019-12-31 | ₩226.71 Billion ≈ $153.64 Million |
+7.08% |
| 2018-12-31 | ₩211.72 Billion ≈ $143.48 Million |
-4.18% |
| 2017-12-31 | ₩220.95 Billion ≈ $149.74 Million |
+5.25% |
| 2016-12-31 | ₩209.93 Billion ≈ $142.26 Million |
+2.34% |
| 2015-12-31 | ₩205.14 Billion ≈ $139.02 Million |
+7.72% |
| 2014-12-31 | ₩190.43 Billion ≈ $129.05 Million |
+12.66% |
| 2013-12-31 | ₩169.03 Billion ≈ $114.55 Million |
+9.93% |
| 2012-12-31 | ₩153.76 Billion ≈ $104.20 Million |
+2.09% |
| 2011-12-31 | ₩150.62 Billion ≈ $102.07 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Kyung Dong Pharmaceutical Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 19361453703000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩193.61 Billion | 84.79% |
| Other Components | ₩34.74 Billion | 15.21% |
| Total Equity | ₩228.36 Billion | 100.00% |
Kyung Dong Pharmaceutical Co. Ltd Competitors by Market Cap
The table below lists competitors of Kyung Dong Pharmaceutical Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vizsla Copper Corp
V:VCU
|
$80.34 Million |
|
Ratchaphruek Hospital Public Company Limited
BK:RPH
|
$80.35 Million |
|
Air T Inc
NASDAQ:AIRT
|
$80.36 Million |
|
U-Best Polymer Industry Co Ltd
TWO:4714
|
$80.37 Million |
|
Inoue Rubber (Thailand) Public Company Limited
BK:IRC
|
$80.28 Million |
|
Pansar Bhd
KLSE:8419
|
$80.27 Million |
|
Panram International
TWO:8088
|
$80.23 Million |
|
Financeira Alfa S.A. - Crédito Financiamento e Investimentos
SA:CRIV3
|
$80.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kyung Dong Pharmaceutical Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 220,060,755,990 to 228,357,460,080, a change of 8,296,704,090 (3.8%).
- Net income of 8,528,662,000 contributed positively to equity growth.
- Dividend payments of 8,082,531,000 reduced retained earnings.
- Other factors increased equity by 7,850,573,090.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩8.53 Billion | +3.73% |
| Dividends Paid | ₩8.08 Billion | -3.54% |
| Other Changes | ₩7.85 Billion | +3.44% |
| Total Change | ₩- | 3.77% |
Book Value vs Market Value Analysis
This analysis compares Kyung Dong Pharmaceutical Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.65x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩8926.12 | ₩5040.00 | x |
| 2017-12-31 | ₩9371.12 | ₩5040.00 | x |
| 2018-12-31 | ₩8941.38 | ₩5040.00 | x |
| 2019-12-31 | ₩9574.44 | ₩5040.00 | x |
| 2020-12-31 | ₩9461.29 | ₩5040.00 | x |
| 2021-12-31 | ₩9540.40 | ₩5040.00 | x |
| 2022-12-31 | ₩9468.64 | ₩5040.00 | x |
| 2023-12-31 | ₩8409.41 | ₩5040.00 | x |
| 2024-12-31 | ₩8168.01 | ₩5040.00 | x |
| 2025-12-31 | ₩7793.77 | ₩5040.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kyung Dong Pharmaceutical Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.73%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.35%
- • Asset Turnover: 0.61x
- • Equity Multiplier: 1.41x
- Recent ROE (3.73%) is below the historical average (6.02%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 13.47% | 15.94% | 0.69x | 1.23x | ₩5.23 Billion |
| 2012 | 5.34% | 6.60% | 0.66x | 1.23x | ₩-7.17 Billion |
| 2013 | 11.13% | 14.17% | 0.66x | 1.18x | ₩1.91 Billion |
| 2014 | 12.89% | 16.00% | 0.67x | 1.20x | ₩5.49 Billion |
| 2015 | 6.89% | 9.30% | 0.65x | 1.14x | ₩-6.38 Billion |
| 2016 | 8.39% | 11.10% | 0.67x | 1.14x | ₩-3.38 Billion |
| 2017 | 9.27% | 11.52% | 0.71x | 1.14x | ₩-1.62 Billion |
| 2018 | 2.48% | 2.92% | 0.70x | 1.22x | ₩-15.93 Billion |
| 2019 | 8.88% | 11.40% | 0.61x | 1.27x | ₩-2.54 Billion |
| 2020 | 4.75% | 7.17% | 0.60x | 1.11x | ₩-13.76 Billion |
| 2021 | 4.88% | 7.13% | 0.61x | 1.12x | ₩-13.31 Billion |
| 2022 | 4.73% | 6.66% | 0.59x | 1.21x | ₩-13.56 Billion |
| 2023 | -9.08% | -12.73% | 0.56x | 1.28x | ₩-43.53 Billion |
| 2024 | 2.49% | 2.82% | 0.64x | 1.38x | ₩-16.54 Billion |
| 2025 | 3.73% | 4.35% | 0.61x | 1.41x | ₩-14.31 Billion |
Industry Comparison
This section compares Kyung Dong Pharmaceutical Co. Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $65,947,832,531
- Average return on equity (ROE) among peers: -7.43%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kyung Dong Pharmaceutical Co. Ltd (011040) | ₩231.58 Billion | 13.47% | 0.33x | $80.33 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $114.32 Billion | 10.17% | 0.61x | $2.37 Billion |
| DongKoo Bio & Pharma Co. Ltd. (006620) | $105.33 Billion | 1.93% | 1.32x | $22.84 Million |
| NatureCell Co.Ltd (007390) | $62.68 Billion | -30.10% | 0.37x | $884.84 Million |
| Sam-A Pharm. Co. Ltd (009300) | $79.92 Billion | 4.39% | 0.39x | $57.91 Million |
| WooGene B&G Co. Ltd (018620) | $18.56 Billion | 6.88% | 0.41x | $47.07 Million |
| Oscotec Inc (039200) | $28.83 Billion | -91.10% | 0.70x | $713.20 Million |
| EstechPharma Co. Ltd (041910) | $89.25 Billion | 7.38% | 0.10x | $43.30 Million |
| Komipharm International Co. Ltd (041960) | $65.54 Billion | 20.01% | 0.87x | $370.23 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $29.11 Billion | 3.53% | 0.43x | $26.69 Million |
About Kyung Dong Pharmaceutical Co. Ltd
Kyung Dong Pharmaceutical Co., Ltd. produces and sells specialized and general medicines in South Korea. It offers prescription medicines for liver therapy, antispasmodic, antidiabetic, antiviral, corticosteroid, androgen alopecia, muscle relaxant, antimigraine, vitamin, antifungal, endocrinal, urology, antibacterial, cardiovascular, pain/inflammation, smoking cessation aid, gastrointestinal, ant… Read more